MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$706,046K
Proceeds from issuance /
public offering of...
$189,249K
Proceeds from exercise of
awards under equity...
$8,459K
Net cash provided by
(used in) investing...
$255,281K
Net cash provided by
financing activities
$189,216K
Canceled cashflow
$450,765K
Canceled cashflow
$8,492K
Net increase
(decrease) in cash, cash...
$31,897K
Canceled cashflow
$412,600K
Purchases of marketable
securities
$441,263K
Purchases of property and
equipment
$9,502K
Stock-based compensation
expense
$99,633K
Depreciation and
amortization
$11,183K
Deferred research and
development funding...
$6,972K
Right-of-use asset
amortization for finance...
$3,629K
Other non-current
assets
-$772K
Accruals and other
current liabilities
$465K
Other non-cash items
-$49K
Payments for finance
lease right-of-use...
$8,168K
Issuance costs related to
the royalty...
$324K
Net cash used in
operating activities
-$412,600K
Canceled cashflow
$122,703K
Net loss
-$512,540K
Net accretion of
discounts on marketable...
$10,253K
Accounts payable
-$7,520K
Non-cash adjustment to
operating lease expense
$4,450K
Prepaid expenses and
other current assets
$540K
Back
Back
Cash Flow
source: myfinsight.com
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)